ProPhase Labs making progress on multiple fronts, says H.C. Wainwright
The Fly

ProPhase Labs making progress on multiple fronts, says H.C. Wainwright

H.C. Wainwright reiterates a Buy rating and $15 price target on ProPhase Labs. The company’s Q4 revenue beat the firm’s estimate, though net loss was lower than forecast primarily due to a one-time year-end charge of $5.9M related to bad debt write-offs, the analyst tells investors in a research note. The company is making progress on multiple fronts to help offset Covid testing revenue loss in the coming quarters, which may help drive long-term growth going forward, H.C. Wainwright says.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on PRPH:

Related Articles
GlobeNewswireProPhase Labs to Present at August 20th Virtual Investor Summit Microcap Event
TheFlyProPhase Labs reports Q2 EPS (33c) vs (20c) last year
TheFlyProPhase Labs announces collaboration with Forward Heathcare Consultants
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App